Voyager Therapeutics(VYGR) Prnewswire·2025-02-18 22:57Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Voyager Therapeutics and its officers or directors [1] Group 1: Company Developments - On February 11, 2025, Voyager announced it would assess alternate payloads for its gene therapy program targeting SOD1 amyotrophic lateral sclerosis (ALS), citing emerging preclinical data indicating that the siRNA payload component of VY9323 does not meet their standards due to off-target effects [2] - Following this announcement, Voyager's stock price dropped by 4.21 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]